– CONV01-α is an actinium-225 labeled radioantibody with proven efficacy and safety in multiple Phase 1/2 trials in prostate cancer patients – Convergent Therapeutics will conduct Phase 2 clinical trials in 2024 preparing for a registrational program in 2025 CAMBRIDGE, Mass., April 2,…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.